News &amp; Updates

The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.

Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?

26 Oct 2021

Baricitinib prevents death in critically ill COVID-19 patients

The oral selective JAK1/2 inhibitor baricitinib significantly reduces the risk of death in critically ill COVID-19 patients who are on invasive mechanical ventilation (IMV) or ECMO*, when used in combination with standard care, according to the addendum study of the COV-BARRIER trial presented at IDWeek 2021.

Baricitinib prevents death in critically ill COVID-19 patients

26 Oct 2021

Everolimus helps fight recurrent thymic neuroendocrine neoplasia

Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.

Everolimus helps fight recurrent thymic neuroendocrine neoplasia

26 Oct 2021

Therapeutic heparin may reduce death, bleeding risks in moderate COVID-19

Use of therapeutic heparin does not appear to significantly reduce the death, mechanical ventilation, or intensive care unit (ICU) admission in hospitalized patients with moderate COVID-19 and increased D-dimer levels, reveals a study. However, it is associated with a significantly lower chances of all-cause death and reduced risk of major bleeding.

Therapeutic heparin may reduce death, bleeding risks in moderate COVID-19

26 Oct 2021

Outpatient dose-adjusted EPOCH for B-cell lymphoma proven safe, feasible

A recent study has shown the safety and feasibility of routine outpatient administration of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH), with a positive annual impact on margin amounting to $1,444,548 at a comprehensive cancer centre.

Outpatient dose-adjusted EPOCH for B-cell lymphoma proven safe, feasible

Survival comparable in erlotinib-treated patients with, without renal insufficiency

Overall survival (OS) is similar between patients with and without renal insufficiency who have been treated with erlotinib, reports a study. Progression-free survival (PFS) is about 6 months shorter in PFS patients with classical mutation relative to those with RI, albeit statistically nonsignificant.

Survival comparable in erlotinib-treated patients with, without renal insufficiency

Study pinpoints factors linked to HPV vaccine series completion among teens

Individual- and community-level factors, such as age and travel distance to the clinic, among others, exert influence on the completion of human papillomavirus two-dose vaccine series among adolescents, according to a study.

Study pinpoints factors linked to HPV vaccine series completion among teens

PRONOUNCE: Relative cardiovascular safety of GnRH antagonists vs agonists still unresolved

The gonadotropin-releasing hormone (GnRH) antagonist degarelix and the GnRH agonist leuprolide appear to be similar in terms of the rate of cardiovascular events in a cohort of patients with prostate cancer, according to the results of the PRONOUNCE trial.

PRONOUNCE: Relative cardiovascular safety of GnRH antagonists vs agonists still unresolved

Molnupiravir pill: A game-changer in COVID-19?

24 Oct 2021 by

The investigational oral antiviral pill molnupiravir significantly slashed the risk of hospitalization or death by half in nonhospitalized adults with mild-to-moderate COVID-19, according to interim data from the phase III MOVe-OUT trial.

Molnupiravir pill: A game-changer in COVID-19?

Dose-capping chemoradiotherapy tied to higher recurrence in rectal cancer